Skip to main content
Premium Trial:

Request an Annual Quote

Ingenium Expands Drug Discovery Collaboration with Elan

NEW YORK, Oct. 6 (GenomeWeb News) - Ingenium Pharmaceuticals said today that it has expanded its drug discovery partnership with Elan to include areas outside pain management.

 

In March, the companies inked a deal under which Ingenium uses its functional genomics tools to identify and clone for Elan molecular targets involved in the molecular mechanisms involved in the control of pain.

 

According to Ingenium, it has been producing genetically altered mouse models for Elan's use in pain management drug target validation.  With the expansion of the deal, it will produce additional models to be used in other areas of research.

 

Specific terms of the deal were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.